Clinical Approach to Antibiotic Failure

Medical Clinics of North America

Volumn 90, Issue 6, 2006, Pages 1265-1277

  Schlossberg, David ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; ETHAMBUTOL; ISONIAZID; LINEZOLID; METRONIDAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; ASPIRATION PNEUMONIA; BACTERIAL INFECTION; DECUBITUS; DRUG TREATMENT FAILURE; FEVER; HUMAN; IMMUNE DEFICIENCY; LUNG EMBOLISM; MALABSORPTION; MEDICATION ERROR; NONHUMAN; PARADOXICAL DRUG REACTION; PHLEBITIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; URINARY TRACT INFECTION;

ABSCESS; ALGORITHMS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; TREATMENT FAILURE;

EID: 33751014305     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.07.004     Document Type: Review

References (17)

1. In: Cunha B.A. (Ed). Infectious diseases in critical care medicine (1998), Marcel Dekker, New York
2. Falagas M.E., and Vergidis P.I. Narrative review: diseases that masquerade as infectious cellulitis. Ann Intern Med 142 1 (2005) 47-55
3. Donlan R.M. Biofilm formation: a clinically relevant microbiological process. Clin Infect Dis 33 (2001) 1387-1392
4. Pankey G.A., and Sabath L.D. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. CID 38 (2004) 864-870
5. Lewis II J.S., and Jorgensen J.H. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned?. CID 40 (2005) 280-285
6. Perlman D.C., Segal Y., Rosenkranz S., et al. The clinical pharmacokinetics of rifampin and etahmbutol in HIV-infected persons with tuberculosis. CID 41 (2005) 1638-1647
7. Tappero J.W., Bradford W.Z., Agerton T.B., et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. CID 41 (2005) 461-469
8. Hessen T.H., and Kaye D. Principles of use of antibacterial agents. Infect Dis Clin N Am 18 (2004) 435-450
9. Tunkel A.R. Acute meningitis. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious disease. 6th edition (2005), Elsevier, Philadelphia
10. Silverman J.A., Mortin L.I., Vanpraagh A.D., et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152
11. Schmidt-Ioanas M., de Roux A., and Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr Opin Crit Care 11 (2005) 481-486
12. Levison M.E. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin N Am 18 (2004) 451-465
13. Schentag J.J., Gilliland K.K., and Paladino J.A. What have we learned from pharmacokinetic and pharmacodynamic theories?. CID 32 (2001) S39-S46
14. Craig W.A. Does the dose matter?. CID 33 (2001) S233-S237
15. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. CID 26 (1998) 1-12
16. Liu P., and Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin N Am 17 (2003) 599-613
17. Barza M. Pharmacologic principles. In: Gorbach S.L., Bartlett J.G., and Blacklow N.R. (Eds). Infectious diseases. 3rd edition (2004), Lippincott Williams & Williams, Philadelphia